Anthem Inc., now operating as Elevance Health, faces intensified regulatory scrutiny in 2026 focused on Medicare Advantage billing practices, Pharmacy Benefit Manager (PBM) transparency through its Carelon division, and strict antitrust enforcement. Federal agencies like the DOJ and FTC are increasingly challenging vertical integration and data-driven risk adjustment strategies to ensure market competition and consumer protection.
The Evolution of Regulatory Pressure on Anthem Inc.
While the corporate entity rebranded to Elevance Health in June 2022 to reflect a broader health-services focus, the "Anthem" name remains synonymous with its Blue Cross Blue Shield licensed insurance products. In 2026, the regulatory environment for large-scale health insurers has shifted from reactive enforcement to proactive oversight. This transition is largely driven by the federal government's attempt to stabilize the healthcare economy and address the rising costs of private-public partnerships.
Historically, Anthem Inc. found itself in the crosshairs during the massive 2015 data breach and the subsequent $115 million settlement, as well as the landmark 2017 antitrust ruling that blocked its $54 billion merger with Cigna. Today, the "crosshairs" have moved. Regulators are no longer just looking at size; they are scrutinizing the interconnectivity of insurance providers with pharmacy benefits, healthcare delivery, and data analytics subsidiaries.
The Shift Toward Vertical Integration Oversight
For decades, the primary concern for regulators was horizontal consolidation—one insurer buying another. However, as Anthem/Elevance expanded its Carelon brand, it began internalizing services like pharmacy management, behavioral health, and complex care. In 2026, the Federal Trade Commission (FTC) is closely examining whether this vertical integration creates "walled gardens" that stifle competition and limit patient choice.
When a company like Anthem owns both the payer and the service provider, regulators worry about self-dealing. This includes steering members toward internal services even if a third party offers a more cost-effective or higher-quality option. The regulatory focus is now on ensuring that internal transfers and "intercompany" revenue do not mask anti-competitive behavior.
Medicare Advantage and Risk Adjustment Audits
A primary area where Anthem Inc. remains in the regulatory crosshairs involves Medicare Advantage (MA). As of 2026, the Centers for Medicare & Medicaid Services (CMS) has implemented more aggressive Risk Adjustment Data Validation (RADV) audits. These audits are designed to identify and recover overpayments caused by inaccurate diagnostic coding.
The Mechanism of Upcoding Allegations
The core of the dispute often centers on Hierarchical Condition Category (HCC) coding. Under the MA capitated payment model, the government pays insurers more for patients with more severe health conditions. Regulators have alleged that some insurers, including Anthem's subsidiaries, have engaged in "upcoding"—documenting conditions that were either not supported by the medical record or were not actively being treated.
In 2026, the Department of Justice (DOJ) continues to leverage the False Claims Act to pursue insurers who allegedly systematically exaggerated the illness level of their membership. For Anthem, this means rigorous internal auditing and the implementation of AI-driven compliance tools to ensure that every diagnostic code submitted to CMS is backed by verifiable clinical documentation.
New Standards for 2026
CMS has tightened the window for "extrapolation," a process where if a small sample of records shows a high error rate, the government applies that error rate across the insurer's entire contract. This significantly increases the financial stakes for Anthem. To mitigate this risk, the company has had to overhaul its retrospective chart review processes, ensuring that it not only finds "missing" codes but also deletes "erroneous" ones—a practice regulators are watching with a hawk's eye.
PBM Transparency and the Carelon Scrutiny
Anthem’s pharmacy benefit management (PBM) operations, managed under the CarelonRx brand, are currently under a microscope. In 2026, both state and federal legislators are demanding greater transparency in how PBMs negotiate rebates with drug manufacturers and how those savings are (or are not) passed on to consumers at the pharmacy counter.
The FTC 6(b) Inquiry Legacy
The ongoing fallout from the FTC’s long-term inquiry into the PBM industry continues to impact Anthem. Regulators are specifically looking at:
- Spread Pricing: The practice where a PBM charges a health plan more for a drug than it pays the pharmacy, pocketing the difference.
- Rebate Retention: How much of the "back-end" discounts from pharmaceutical companies are retained as profit versus being used to lower premiums.
- Preferred Networks: Whether PBMs are unfairly disadvantaging independent pharmacies in favor of their own mail-order or retail affiliates.
Anthem has responded by introducing more "transparent" or "cost-plus" pharmacy models, but the regulatory demand for a complete decoupling of PBM profits from drug prices remains a significant headwind.
Antitrust Enforcement and Managed Care Mergers
The 2017 rejection of the Anthem-Cigna merger set a precedent that continues to define the industry in 2026. The DOJ’s Antitrust Division has adopted a "tougher-on-mergers" stance, particularly regarding the potential for monopsony power—where a single large buyer (the insurer) has so much market power that it can unfairly drive down the prices paid to doctors and hospitals, potentially hurting the quality of care.
Localized Market Concentration
While Anthem operates nationally, regulatory scrutiny is often hyper-local. In many states, Anthem is one of only two or three major players. If Anthem seeks to acquire a smaller regional plan or a large multi-specialty physician group, it must now clear higher hurdles than in previous decades.
Regulators are increasingly using the "Potential Competition" doctrine, arguing that even if a merger doesn't create an immediate monopoly, it prevents a company from becoming a future competitor in a new segment. For Anthem, this means organic growth is often favored over acquisition to avoid lengthy and expensive litigation with the DOJ.
Consumer Protection and Mental Health Parity
A rising tide of regulation in 2026 concerns Mental Health Parity. The Mental Health Parity and Addiction Equity Act (MHPAEA) requires that insurers provide the same level of coverage for mental health and substance use disorders as they do for medical and surgical care.
| Regulatory Area | Primary Oversight Body | Key Focus for 2026 |
|---|---|---|
| Medicare Advantage | CMS / DOJ | RADV audits and False Claims Act litigation regarding coding. |
| Pharmacy Benefits | FTC / State AGs | Rebate transparency and the elimination of spread pricing. |
| Market Competition | DOJ Antitrust Division | Preventing monopsony power and vertical integration abuse. |
| Data Privacy | HHS (OCR) | HIPAA compliance in AI applications and telehealth security. |
| Network Adequacy | State Departments of Insurance | Ensuring members have "meaningful access" to in-network providers. |
| Mental Health Parity | Department of Labor (DOL) | Comparing quantitative and non-quantitative treatment limits. |
Anthem has faced criticism and legal challenges regarding "ghost networks"—provider directories that list mental health professionals who are not actually accepting new patients or are no longer in the network. In 2026, federal regulators have introduced stricter "Network Adequacy" standards, requiring insurers to prove that their members can actually access the care they are paying for within a reasonable timeframe and distance.
Data Privacy in the Age of AI
As Anthem integrates more artificial intelligence into its claims processing and prior authorization workflows, it enters a new regulatory frontier. In 2026, the Department of Health and Human Services (HHS) has clarified that HIPAA protections apply fully to AI training sets that use patient data.
Prior Authorization Scrutiny
One of the most contentious "crosshair" issues is the use of AI algorithms to deny claims. Regulators are concerned that automated systems may be programmed to default to denials for expensive treatments, placing an undue burden on patients and providers to appeal. New federal rules in 2026 require a "human-in-the-loop" for all adverse clinical determinations, ensuring that a qualified medical professional—not just an algorithm—reviews denials for medical necessity.
Operational Impacts for Providers and Policyholders
The constant regulatory pressure on Anthem Inc. has direct consequences for the broader healthcare ecosystem. For healthcare providers, this often translates to more rigorous documentation requirements. Because Anthem is being audited by the government, they, in turn, must audit the doctors and hospitals in their network.
For policyholders, these regulatory battles are a double-edged sword. On one hand, government intervention in PBMs and Medicare Advantage aims to lower overall costs and prevent fraud. On the other hand, the high cost of compliance can sometimes lead to narrower provider networks or increased administrative friction (such as more frequent prior authorization requirements) as the insurer seeks to control costs and ensure data accuracy.
Frequently Asked Questions
Is Anthem Inc. still the company's legal name?
As of 2022, the parent company is officially Elevance Health, Inc. However, it continues to use the "Anthem" brand for its Blue Cross Blue Shield insurance plans in 14 states. In regulatory filings and legal proceedings, you will often see both names mentioned, as many of the historical regulatory issues originated under the Anthem Inc. banner.
Why is the DOJ suing Anthem over Medicare Advantage?
The DOJ often intervenes in "qui tam" (whistleblower) lawsuits or initiates its own actions when it believes an insurer has systematically overcharged the Medicare program. The primary allegation is usually that the insurer's "risk adjustment" program was one-sided—aggressively looking for additional diagnoses to increase government payments while ignoring errors that should have resulted in lower payments.
How does the FTC's focus on PBMs affect Anthem's Carelon division?
The FTC is concerned that PBMs like CarelonRx create a conflict of interest. Because Carelon is owned by the same company that owns the insurance plan, regulators want to ensure that Carelon isn't overcharging the plan (and thus the policyholders) or unfairly excluding competing pharmacies that might offer lower prices.
What happened to the Cigna merger?
The merger was officially terminated in 2017 after the DOJ won a permanent injunction to block it. The courts agreed with regulators that the merger would significantly reduce competition in the "national accounts" market (large employers) and would lead to higher prices and less innovation. The two companies spent years in litigation following the breakup over "reverse breakup fees" and damages.
Are "Ghost Networks" illegal?
While not always "illegal" in a criminal sense, maintaining inaccurate provider directories violates various state and federal consumer protection and network adequacy laws. In 2026, regulators have increased fines for insurers who fail to keep their directories updated, as "ghost networks" prevent patients from accessing the mental health and specialty care guaranteed by their insurance contracts.
Practical Recommendations for Stakeholders
For those interacting with Anthem/Elevance Health in this heightened regulatory climate, several proactive steps are recommended:
- For Healthcare Providers: Prioritize "Clinical Integrity" in documentation. Ensure that every HCC code submitted during an encounter is supported by the "M.E.A.T." criteria (Monitor, Evaluate, Assess, or Treat). This reduces the risk of claim reversals during internal or federal audits.
- For Investors: Monitor the "Medical Loss Ratio" (MLR) and regulatory settlement reserves. Changes in RADV audit rules or PBM legislation can have immediate impacts on the company's bottom line and stock valuation.
- For Policyholders: Utilize the "Transparency in Coverage" tools provided by the insurer. In 2026, these tools are more robust due to federal mandates, allowing you to compare the actual negotiated rates for procedures across different providers.
- For Compliance Officers: Review the latest HHS Office of Inspector General (OIG) Work Plan regularly. The OIG frequently lists its focus areas for the coming year, providing a roadmap of where the "crosshairs" will be aimed next.
The regulatory scrutiny surrounding Anthem Inc. (Elevance Health) is a reflection of the larger struggle to balance corporate profitability with the public's need for affordable, accessible, and transparent healthcare. As 2026 progresses, the company's ability to adapt its compliance frameworks to these evolving federal demands will determine its long-term stability in the managed care market.